Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8059109 | 1.00 | ESR2 (0.40) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4215865 | 1.00 | ESR2 (0.40) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4203446 | 0.96 | ESR2 (0.38) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL8059842 | 0.88 | GPR119 (0.46) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL8059846 | 0.88 | GPR119 (0.46) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4206674 | 0.88 | GPR119 (0.46) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4011248 | 0.88 | ESR2 (0.43) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4201307 | 0.88 | ESR2 (0.43) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4014808 | 0.88 | ESR2 (0.43) | ESR2GPR119NR1H2MAP4K4PDE10A | |
| SCHEMBL4209371 | 0.88 | ESR2 (0.43) | ESR2GPR119NR1H2MAP4K4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
| WO-2009079765-A1 | COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR | CASCADE THERAPEUTICS INC. (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | ESR2 550/4885GPR119 220/4885NR1H2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.